N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE
Reason given: lack of patients
Key facts
- Where
- Caen, FranceSee the site
- Phase
- Phase 2
Where in France
- CHU CaenCaen, FranceNo longer taking part
Trial details
- Who runs it
- University Hospital, Caen
- Trial code
- NCT04920448
- Record updated
- 25 July 2025
- Original description
The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.Read full original descriptionShow less
TOLERANCE STUDY OF N-ACETYLCYSTEINE FOR THROMBOLYSIS IN THE ACUTE PHASE OF ISCHEMIC STROKE / ETUDE DE TOLERANCE DE LA N-ACETYLCYSTEINE POUR LA THROMBOLYSE A LA PHASE AIGUË DE L'INFARCTUS CEREBRAL
The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.
Inclusion: Patient presenting with an acute ischemic stroke (non lacunar) as assessed by cerebral imaging (either CT or MRI), with or without visible vessel occlusion; Patient eligible to intravenous thrombolysis according to current criteria, including patients who will also benefit from endovascular treatment (if eligible); Personal or familial consent to participate in the study.
Exclusion: Daily treatment with Nitrovasodilator before the inclusion; Known history of prior treatment with vitamin-K antagonist or direct oral anticoagulant; Known hypersensitivity to N-Acetylcysteine or to any excipient from the formulation; Known asthma or chronic obstructive pulmonary disease requiring bronchodilatators or steroids; Known history of severe hepatopathy including cirrhosis, portal hypertension (esophageal varices) and evolutive hepatopathy; Women of childbearing age (age < or = to 50); Coma and/or NIHSS <4 or ≥20; Participation to another interventional study if it requires administration of an experimental treatment in the first 3 days after NAC treatment.